Shionogi & Co., Ltd. along with Maze Therapeutics, Inc. have declared a global exclusive licensing deal for MZE001, an innovative therapy aimed at addressing Pompe Disease.

Kite has provided numerous important updates regarding their collaborative project on anitocabtagene autoleucel (anito-cel) for treating multiple myeloma.

CytomX Therapeutics Reports Promising Early Stage 1a Results for its Solo Therapy CX-904 (EGFRxCD3 PROBODY® T-cell Engager) in Dose Escalation Study.

Freeline Announces Promising Results from Initial Study of FLT201, New Gene Therapy for Gaucher Disease, at ASGCT's 27th Meeting in a Keynote Speech.

TScan Therapeutics has started dosing the first participant in a Phase 1 study to assess TCR-T therapy against solid tumors.

Fate Therapeutics Reports Initial Treatment of a Lupus Patient in its Phase 1 Study for the FT819 CAR T-cell Off-the-shelf Therapy.

Acepodia Reveals Initial Results from Phase 1 Study of ACE1831, the First Anti-CD20 Antibody-Linked Allogeneic Gamma Delta T Cell Treatment for Non-Hodgkin’s Lymphoma.

Sobi announced that the European Commission has approved Aspaveli® (pegcetacoplan) to treat adults with paroxysmal nocturnal haemoglobinuria and haemolytic anaemia.

Phanes Therapeutics, Inc. has entered into a clinical supply deal with Roche to test PT217 alongside an anti-PD-L1 treatment.

Neurocrine Biosciences, Inc. has launched its Phase 1 clinical trial, marking the first time humans are being evaluated.

Biotheryx, Inc. revealed that their Investigational New Drug application for BTX-9341, an innovative bifunctional degrader targeting cyclin-dependent kinase 4/6 (CDK4/6).

Neurogene revealed promising safety results from its Phase 1/2 study on NGN-401, a gene therapy for Rett Syndrome.